Education Blog for Healthcare Professionals

Posts Tagged ‘Pulmonary embolism’

Rivaroxaban (Xarelto) and PE

| Anticoagulants, Therapy, Uncategorized, Xarelto (Rivaroxaban) | Comments Off on Rivaroxaban (Xarelto) and PE

Stephan Moll, MD writes…

Good news: The large phase 3 clinical trial comparing 3-12 months treatment of Rivaroxaban (Xarelto) with warfarin in patients with newly diagnosed pulmonary embolism was published on 3-26-2012 in the New England Journal of Medicine [reference 1], showing that Rivaroxaban was (a) noninferior to warfarin in its efficacy, (b) caused the same amount of clinically relevant bleeding (composite of major and clinically relevant nonmajor bleeding), and (c) caused less major bleeding Read the rest of this entry »

New ACCP Guidelines – DVT and PE: Highlights and Summary

| Anticoagulants, Deep Vein Thrombosis (DVT), Guideline, Pulmonary Embolism, Uncategorized | Comments Off on New ACCP Guidelines – DVT and PE: Highlights and Summary

Stephan Moll, MD writes…  This month the American College of Chest Physicians (ACCP) published its new (2012) guidelines regarding anticoagulation and management of various thrombotic disorders, replacing the 2008 edition. The details of the new guidelines can be found here Read the rest of this entry »

Incidentally Discovered DVT, PE or Other Clots

| Cancer and blood clots, Clots in unusual locations, Deep Vein Thrombosis (DVT), Pulmonary Embolism, Uncategorized | 3 Comments »

General comments

CT or MRI scans will occasionally detect an incidental iliofemoral DVT, PE or intra-abdominal thrombosis (IVC, portal, splenic, mesenteric or renal vein). This is particularly common in cancer patients undergoing staging CT scans. When such an incidental, asymptomatic venous thromboembolism (VTE) is discovered, the question arises whether the patient should be treated with anticoagulants or not. Read the rest of this entry »

DVT and PE: How Long to Treat With Anticoagulants?

| Anticoagulants, Deep Vein Thrombosis (DVT), Pulmonary Embolism, Therapy, Uncategorized | Comments Off on DVT and PE: How Long to Treat With Anticoagulants?

Explanation for Patients

The complex topic of “Length of Anticoagulant Treatment” for patients with VTE  is being addressed in a blog entry written for patients, found on the Clot Connect patient education blog (here).

For the Health Care Professional

Well respected treatment guidelines exist [ref 1,2]. Read the rest of this entry »

Apixaban (Eliquis®) – Another New Oral Anticoagulant

| Anticoagulants, Therapy, Uncategorized | Comments Off on Apixaban (Eliquis®) – Another New Oral Anticoagulant

Good news.  Another one of the new oral anticoagulants in development,  Apixaban (Eliquis®), has moved forward.  On May 20th, 2011, the European Medicines Agency (EMA) approved Eliquis® for DVT prevention after orthopedic surgery (hip and knee replacement) in the 27 countries of the European Community. In the U.S., however, Eliquis® is still some way away from getting FDA approval Read the rest of this entry »

Testosterone and Thrombosis

| Arterial Clots, Deep Vein Thrombosis (DVT), Pulmonary Embolism, Therapy, Uncategorized | 1 Comment »

Testosterone Replacement Therapy

Replacement therapy with low doses of testosterone does not adversely affect blood coagulation status [ref 1] and does not appear to increase the risk of venous or arterial thrombosis. Thrombosis is not listed as a potential side effect in the commly used drug compendium (Micromedex). Furthermore, the 2006 “Clinical Practice Guideline” from the Endocrine Society also does not list thrombosis as a side effect of testosterone replacement therapy, or a previous history of blood clots as a reason not to give testosterone replacement therapy [ref 2]. However, the Androgel® package insert (prescribing information) lists “blood clots in the legs” as a potential side effect Read the rest of this entry »